About UCSF Search UCSF UCSF Medical Center

Susana Ortiz-Urda, MD, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ortiz-urda_susana

Assistant Clinical Professor, Department of Dermatology, UCSF

OrtizSM@derm.ucsf.edu

Phone: (415) 353-9900 (appts)
Box 0316, UCSF
San Francisco, CA 94143-0316

View on UCSF Profiles


Additional Websites


Education

University of Vienna Medical School, M.D., 1998, Medicine
Rappersberger, University of Vienna, Ph.D, 1998, Biology
University of Vienna, Research Fellow, 1999, Dermatology
AKH Vienna, Research Resident, 2001, Dermatology
Stanford University, Postdoctoral Fellowship, 2005, Epithelial Biology
The Brooklyn Hospital Center, NY, Internship, 2006, Medicine
Stanford University, Resident, 2010, Dermatology
University of California, San Francisco, Research Fellowship, 2010, Derm-Oncology

 

Professional Experience

  • 2010-2011
    University of California, San Francisco, Assistant Professor in Dermatology, Dermatology
  • 2007-present
    University of Vienna, Professor in Experimental Dermatology, Dermatology
  • 2011-present
    University of California, San Francisco, Co-Director, Melanoma program, Dermatology

Honors & Awards

  • 2007
    Kardinal-Innitzer-Foerderungspreis for outstanding Science in Dermatology
  • 2007
    Habilitation for Experimental Dermatology (Univ.-Doz. i.e. professor) University of Vienna
  • 2008
    Unilever Award from the Austrian Society for Dermatology and Venereology
  • 2011
    American Cancer Society Individual Research Award
  • 2011
    American Skin Association Scholar Award
  • 2011
    Dermatology Foundation Career Development Award
  • 2011
    K08 Award National Institute of Health

Selected Publications

  1. Posch C, Ortiz-Urda S. NRAS mutant melanoma--undrugable? Oncotarget. 2013 Apr; 4(4):494-5.
    View on PubMed
  2. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A. 2013 Mar 5; 110(10):4015-20.
    View on PubMed
  3. Chong K, Daud A, Ortiz-Urda S, Arron ST. Cutting edge in medical management of cutaneous oncology. Semin Cutan Med Surg. 2012 Jun; 31(2):140-9.
    View on PubMed
  4. Reuter JA, Ortiz-Urda S, Kretz M, Garcia J, Scholl FA, Pasmooij AM, Cassarino D, Chang HY, Khavari PA. Modeling inducible human tissue neoplasia identifies an extracellular matrix interaction network involved in cancer progression. Cancer Cell. 2009 Jun 2; 15(6):477-88.
    View on PubMed
  5. Waterman EA, Sakai N, Nguyen NT, Horst BA, Veitch DP, Dey CN, Ortiz-Urda S, Khavari PA, Marinkovich MP. A laminin-collagen complex drives human epidermal carcinogenesis through phosphoinositol-3-kinase activation. Cancer Res. 2007 May 1; 67(9):4264-70.
    View on PubMed
  6. Ortiz-Urda S, Garcia J, Green CL, Chen L, Lin Q, Veitch DP, Sakai LY, Lee H, Marinkovich MP, Khavari PA. Type VII collagen is required for Ras-driven human epidermal tumorigenesis. Science. 2005 Mar 18; 307(5716):1773-6.
    View on PubMed
  7. Marker M, Ortiz-Urda S, Lilgenau N, Rappersberger K. [Erythema induratum-nodular vasculitis]. J Dtsch Dermatol Ges. 2004 Mar; 2(3):206-14; quiz 215.
    View on PubMed
  8. Valencak J, Ortiz-Urda S, Heere-Ress E, Kunstfeld R, Base W. Carbamazepine-induced DRESS syndrome with recurrent fever and exanthema. Int J Dermatol. 2004 Jan; 43(1):51-4.
    View on PubMed
  9. Ortiz-Urda S, Elbe-B├╝rger A, Smolle J, Marquart Y, Chudnovsky Y, Ridky TW, Bernstein P, Wolff K, Rappersberger K. The plant lectin wheat germ agglutinin inhibits the binding of pemphigus foliaceus autoantibodies to desmoglein 1 in a majority of patients and prevents pathomechanisms of pemphigus foliaceus in vitro and in vivo. J Immunol. 2003 Dec 1; 171(11):6244-50.
    View on PubMed
  10. Ortiz-Urda S, Lin Q, Yant SR, Keene D, Kay MA, Khavari PA. Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer. Gene Ther. 2003 Jul; 10(13):1099-104.
    View on PubMed
  11. Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Calos MP, Khavari PA. PhiC31 integrase-mediated nonviral genetic correction of junctional epidermolysis bullosa. Hum Gene Ther. 2003 Jun 10; 14(9):923-8.
    View on PubMed
  12. Ortiz-Urda S, Rappersberger K. [New immunosuppressive agents for treating psoriasis]. Hautarzt. 2003 Mar; 54(3):230-6.
    View on PubMed
  13. Ortiz-Urda S, Lin Q, Green CL, Keene DR, Marinkovich MP, Khavari PA. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J Clin Invest. 2003 Jan; 111(2):251-5.
    View on PubMed
  14. Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Fang M, Calos MP, Khavari PA. Stable nonviral genetic correction of inherited human skin disease. Nat Med. 2002 Oct; 8(10):1166-70.
    View on PubMed
  15. Schmuth M, Yosipovitch G, Williams ML, Weber F, Hintner H, Ortiz-Urda S, Rappersberger K, Crumrine D, Feingold KR, Elias PM. Pathogenesis of the permeability barrier abnormality in epidermolytic hyperkeratosis. J Invest Dermatol. 2001 Oct; 117(4):837-47.
    View on PubMed
  16. Schaeppi H, Bauer JW, Hametner R, Metze D, Ortiz-Urda S, Salmhofer W, Rappersberger K, Hintner H. A localized variant of paraneoplastic pemphigus: acantholysis associated with malignant melanoma. Br J Dermatol. 2001 Jun; 144(6):1249-54.
    View on PubMed

Go to UCSF Profiles, powered by CTSI